Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling.

OBJECTIVE To determine the incremental cost-effectiveness of the transdermal nicotine patch. DESIGN Decision analytic model that evaluated the incremental cost-effectiveness of the addition of the nicotine patch to smoking cessation counseling. Costs were based on physician time and the retail cost of the nicotine patch, and benefits were based on quality-adjusted life years (QALYs) saved. PATIENTS Male and female smokers aged 25 to 69 years receiving primary care. INTERVENTION Addition of the nicotine patch to physician-based smoking cessation counseling. MAIN OUTCOME MEASURE Costs (1995 dollars) per QALYs save discounted by 3% annually. RESULTS The use of the patch produced 1 additional lifetime quitter at a cost of $7332. The incremental cost-effectiveness of the nicotine patch by age group ranged from $4390 to $10 943 per QALY for men and $4955 to $6983 per QALY for women. A clinical strategy involving limiting prescription renewals to patients successfully abstaining for the first 2 weeks improved the cost-effectiveness of the patch by 25%. CONCLUSIONS The findings provide support both for the routine use of the nicotine patch as an adjunct to physicians' smoking cessation counseling and for health insurance coverage of nicotine patch therapy.

[1]  B. Littenberg,et al.  Screening for hypertension. , 1970, Lancet.

[2]  N. Wald,et al.  How effective is nicotine replacement therapy in helping people to stop smoking? , 1994, BMJ.

[3]  K. Cummings,et al.  Use and effectiveness of transdermal nicotine in primary care settings. , 1994, Archives of family medicine.

[4]  G. Oster,et al.  The economic costs of smoking and benefits of quitting for individual smokers. , 1984, Preventive medicine.

[5]  Torsten Schaub,et al.  Does smoking increase medical care expenditure? , 1983, Social science & medicine.

[6]  M. Horstmann,et al.  Combination of behavioral smoking cessation with transdermal nicotine substitution. , 1989, Addictive behaviors.

[7]  G. Oster,et al.  The cost-effectiveness of counseling smokers to quit. , 1989, JAMA.

[8]  S S Smith,et al.  Predicting smoking cessation. Who will quit with and without the nicotine patch. , 1994, JAMA.

[9]  S. Leischow,et al.  Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling. , 1993, Archives of internal medicine.

[10]  D. Mant,et al.  Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation , 1994, The Lancet.

[11]  M. Russell,et al.  Effect of general practitioners' advice against smoking , 1979, British medical journal.

[12]  M. Jarvik,et al.  Degree of addiction and effectiveness of nicotine gum therapy for smoking. , 1984, The American journal of psychiatry.

[13]  P. F. Adams,et al.  Current estimates from the National Health Interview Survey, 1994. , 1995, Vital and health statistics. Series 10, Data from the National Health Survey.

[14]  T. Abelin,et al.  Effectiveness of a transdermal nicotine system in smoking cessation studies. , 1989, Methods and findings in experimental and clinical pharmacology.

[15]  G. Oster,et al.  Cost-effectiveness of nicotine gum as an adjunct to physician's advice against cigarette smoking. , 1986, JAMA.

[16]  P. Tønnesen,et al.  A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation. , 1991, The New England journal of medicine.

[17]  J. Hollis,et al.  Nicotine chewing gum use in the outpatient care setting. , 1992, The Journal of family practice.

[18]  R. G. Rogers,et al.  Life expectancies of cigarette smokers and nonsmokers in the United States. , 1991, Social science & medicine.

[19]  N. Wald,et al.  Controlled trial of three different antismoking interventions in general practice. , 1984, British medical journal.

[20]  T. Blöndal.  Controlled trial of nicotine polacrilex gum with supportive measures. , 1989, Archives of internal medicine.

[21]  Stewart Mj,et al.  A controlled trial of nicotine chewing gum in a smoking withdrawal clinic. , 1982 .

[22]  M. Fiore,et al.  The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. , 1994, JAMA.

[23]  P. Tønnesen,et al.  Predictors and reasons for relapse in smoking cessation with nicotine and placebo patches. , 1993, Preventive medicine.

[24]  Torsten Schaub,et al.  More on the impact of smoking on medical care expenditures. , 1985, Social science & medicine.

[25]  M. Law,et al.  An analysis of the effectiveness of interventions intended to help people stop smoking. , 1995, Archives of internal medicine.

[26]  T. Abelin,et al.  CONTROLLED TRIAL OF TRANSDERMAL NICOTINE PATCH IN TOBACCO WITHDRAWAL , 1989, The Lancet.

[27]  T. Hodgson,et al.  Cigarette smoking and lifetime medical expenditures. , 1992, The Milbank quarterly.

[28]  H. Schauffler,et al.  Health Insurance Coverage for Smoking Cessation Services , 1993, Health education quarterly.

[29]  A. Cepeda-Benito,et al.  Meta-analytical review of the efficacy of nicotine chewing gum in smoking treatment programs. , 1993, Journal of consulting and clinical psychology.

[30]  E. Gilpin,et al.  Nicotine patch use in the general population: results from the 1993 California Tobacco Survey. , 1995, Journal of the National Cancer Institute.

[31]  W. Rosser,et al.  The impact of routine advice on smoking cessation from family physicians. , 1982, Canadian Medical Association journal.

[32]  R. Hurt,et al.  Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement. , 1994, JAMA.

[33]  P. Erickson,et al.  Years of healthy life. , 1995, Healthy People 2000 statistical notes.

[34]  R. Heidel,et al.  Reducing the Health Consequences of Smoking: 25 Years of Progress. A Report of the Surgeon General. , 1989 .

[35]  H. Sacks,et al.  META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS OF NICOTINE CHEWING-GUM , 1987, The Lancet.

[36]  W. Bickel,et al.  Effect of cost on the self-administration and efficacy of nicotine gum: a preliminary study. , 1991, Preventive medicine.

[37]  M. Raw,et al.  Randomised controlled trial of nicotine chewing-gum. , 1982, British medical journal.

[38]  M. Fiore,et al.  Tobacco dependence and the nicotine patch. Clinical guidelines for effective use. , 1992, JAMA.

[39]  M. Gold.  Cost-effectiveness in health and medicine , 2016 .

[40]  M. Russell,et al.  Effect of nicotine chewing gum as an adjunct to general practitioner's advice against smoking. , 1983 .

[41]  M. Drummond,et al.  Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .

[42]  J. McNeil,et al.  Prospective study of factors predicting outcome of transdermal nicotine treatment in smoking cessation , 1994, BMJ.

[43]  B. Rimer,et al.  Use of transdermal nicotine in a state-level prescription plan for the elderly. A first look at 'real-world' patch users. , 1994, JAMA.

[44]  A. Hjalmarson.  Effect of nicotine chewing gum in smoking cessation. A randomized, placebo-controlled, double-blind study. , 1984, JAMA.

[45]  D. Sachs.  Effectiveness of the 4-mg dose of nicotine polacrilex for the initial treatment of high-dependent smokers. , 1995, Archives of internal medicine.